Show simple item record

dc.contributor.authorStedman, Michael; orcid: 0000-0002-0491-7823
dc.contributor.authorTaylor, Peter
dc.contributor.authorPremawardhana, Lakdasa; orcid: 0000-0003-0931-3700
dc.contributor.authorOkosieme, Onyebuchi; orcid: 0000-0003-2221-992X
dc.contributor.authorDayan, Colin
dc.contributor.authorHeald, Adrian H.; orcid: 0000-0002-9537-4050; email: adrian.heald@manchester.ac.uk
dc.date.accessioned2021-05-20T16:38:35Z
dc.date.available2021-05-20T16:38:35Z
dc.date.issued2021-03-21
dc.date.submitted2020-11-08
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/624578/cen.14414.xml?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/624578/cen.14414.pdf?sequence=3
dc.identifier.citationClinical Endocrinology, volume 94, issue 6, page 980-989
dc.identifier.urihttp://hdl.handle.net/10034/624578
dc.descriptionFrom Wiley via Jisc Publications Router
dc.descriptionHistory: received 2020-11-08, rev-recd 2020-12-14, accepted 2020-12-21, pub-electronic 2021-03-21, pub-print 2021-06
dc.descriptionArticle version: VoR
dc.descriptionPublication status: Published
dc.description.abstractAbstract: Introduction: Recent prescribing policies in England and Wales have imposed significant restrictions on liothyronine prescribing in general practice driven by the prohibitive costs and uncertain benefits of liothyronine in the management of hypothyroidism. However, the impact of these policies on liothyronine usage and costs is still unclear. Methods: Data were downloaded from the NHS monthly General Practice Prescribing Data in England and from the Comparative Analysis System for Prescribing Audit (CASPA) in Wales for 2011–2020. Trends over the period in amount and costs of levothyroxine and liothyronine prescribing were analysed. Results: The total medication costs per year for England Wales for hypothyroidism rose from £60.8 million to £129.8 million in 2015–16 and have since reduced to £88.4 million. Levothyroxine prescriptions have been growing above the population growth rate at 0.7%/annum in England and 1.1% in Wales. The costs/patient/year for liothyronine rose from £550 to £3000 in 2015–16 and has since fallen to £2500. Use of liothyronine as a percentage of levothyroxine started to fall in 2015–16 at 7%/annum in England and 3% in Wales. Nevertheless, 0.5% of levothyroxine‐treated patients continue to receive liothyronine. All Clinical Commission Groups (CCGs) in England continue to have at least one liothyronine prescribing practice and 48.5% of English general practices prescribed liothyronine in 2019–20. Conclusion: In spite of strenuous attempts to limit prescribing of liothyronine in general practice, a significant number of patients continue to receive this therapy. The price differential of liothyronine vs levothyroxine should be examined again in light of the continuing use of liothyronine.
dc.languageen
dc.rightsLicence for VoR version of this article: http://creativecommons.org/licenses/by-nc/4.0/
dc.sourceissn: 0300-0664
dc.sourceissn: 1365-2265
dc.subjectORIGINAL ARTICLE
dc.subjectORIGINAL ARTICLES
dc.subjectcomparison
dc.subjectlevothyroxine
dc.subjectliothyronine
dc.subjectprescribing
dc.subjectT3
dc.subjectT4
dc.subjecttrends
dc.titleTrends in costs and prescribing for liothyronine and levothyroxine in England and wales 2011–2020
dc.typearticle
dc.date.updated2021-05-20T16:38:35Z
dc.date.accepted2020-12-21


Files in this item

Thumbnail
Name:
cen.14414.xml
Size:
9.065Kb
Format:
XML
Thumbnail
Name:
cen.14414.pdf
Size:
1.099Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record